Fabry


Also found in: Dictionary, Medical, Wikipedia.

Fabry

Charles . 1867--1945, French physicist: discovered ozone in the upper atmosphere
References in periodicals archive ?
28, 2015 /PRNewswire/ --Summary Fabry disease is a rare X-linked inherited disorder caused by the deficiency of lysosomal enzyme a-galactosidase A (Nagueh, 2003).
The EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024 forecasts that diagnosed prevalent cases of Fabry disease in the 7MM will increase to 8,037 diagnosed prevalent cases in 2024, at an AGR of 7.
Phil Fabry of Spotlight Dance Cup says he likes to see the choreographer put her own creative spin on a song.
The clinical trial report, Fabry Disease Global Clinical Trials Review, H1, 2013" provides data on the Fabry Disease clinical trial scenario.
Fabry disease is an X-linked hereditary disorder caused by a deficiency of the lysosomal enzyme [alpha]-galactosidase A.
Genzyme Corporation (Nasdaq: GENZ) announced today that the company has begun enrollment in a world-wide post-marketing clinical trial evaluating the efficacy and safety of treating pediatric male patients with mild Fabry disease symptoms with a low-dose regimen of Fabrazyme[R] (agalsidase beta).
We believe the unusual scalability, speed and efficiency of iBio's plant-based protein expression platform technology can make important contributions to rapid development and availability of therapies against orphan diseases such as Fabry Disease," said Robert Erwin, President of iBio.
NYSE-AMEX: PLX, TASE: PLX), announced today that management presented data on the Company's preclinical Fabry program and oral enzyme Gaucher program with experts in the field of lysosomal disorders at a Company-sponsored medical meeting which was recently held in New York City.
A recent study on stroke in this age group revealed that about five per cent of males and approximately three per cent of females with cryptogenic stroke (stroke with unknown origin) suffer from Fabry disease.
NYSE AMEX: IBIO) today announced the engagement of CBR International Corporation (CBR) for strategic regulatory and clinical services to advance iBio's Orphan Drug designated, plant-produced human alpha galactosidase A ("-Gal A") enzyme candidate for development as a therapeutic option for patients with Fabry disease.
16, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal(TM) (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.